

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human GCN2 in direct ELISAs.
Source	Monoclonal Mouse IgG _{2B} Clone # 708210
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human GCN2 Arg22-Lys139 Accession # Q9P2K8
Conjugate	Alexa Fluor 594 Excitation Wavelength: 590 nm Emission Wavelength: 617 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

GCN2, also known as EIF2AK4, is a widely expressed 190 kDa ribosome-associated Ser/Thr kinase that plays an important role in the control of protein translation. In response to amino acid deprivation or UV irradiation, GCN2 phosphorylates the alpha subunit of eukaryotic initiation factor 2 (eIF2α) at Ser51 and induces a delay in entry to S phase of the cell cycle. Increased GCN2 activity in solid tumors enhances the production of amino acids and contributes to tumor cell survival in conditions of nutrient deprivation. GCN2 contains an RWD domain (aa 21-134), a pseudo-kinase domain (aa 296-539), a catalytic domain (aa 590-1001), and a histidyl tRNA synthase-like domain (aa 1022-1493) followed by a C-terminal ribosome interacting region. Alternate splicing generates an isoform with a short deletion in the kinase domain and an isoform that is truncated at the N-terminal end of the kinase domain. Within aa 22-139, human GCN2 shares 91% aa sequence identity with mouse and rat GCN2.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc., and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.